The primary objective of the AMYPAD Prognostic and Natural History Study (PNHS) was to evaluate the value of quantitative PET amyloid imaging measures for predicting progression within an Alzheimer’s disease risk probability spectrum based on quantitative PET amyloid imaging measures, with or without other biomarkers. Through an intimate collaboration with EPAD and other non-EPAD cohorts, we leveraged a Europe-wide network, with all the necessary training and instrumentation to study the earliest stages on the path towards Alzheimer’s disease in a longitudinal fashion.